Skip to content

Clinical efficacy and safety of repetitive transcranial magnetic stimulation combined with bright light therapy for sleep disorders in patients with Alzheimer's disease

Clinical efficacy and safety of repetitive transcranial magnetic stimulation combined with bright light therapy for sleep disorders in patients with Alzheimer's disease

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500105104
Enrollment
Unknown
Registered
2025-06-30
Start date
2025-07-15
Completion date
Unknown
Last updated
2025-07-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's Disease

Interventions

Experimental group:rTMS real stimulation combined with bright light therapy
control group:rTMS real stimulation combined with natural light
control group:Sham rTMS combined with bright light therapy
control group:Sham rTMS stimulation combined with natural light

Sponsors

Beijing Geriatric Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Right-handed; Age >=60 years old, both sexes; 2. Can cooperate with rTMS and bright light treatment; 3. Mild and moderate AD: Montreal Cognitive Assessment (MoCA, Beijing version) score > 15, CDR < 2 (mild and moderate dementia); The disease duration was less than 10 years; No long-term use of sedative-hypnotic drugs, or stable use of AD treatment drugs for more than 4 weeks, and no drug dose adjustment during the treatment period; 4. The degree of education is the third grade of primary school or above; 5. Subjects and their guardians or legal representatives agreed to participate in the study and signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Complicated with other neurological and mental diseases, severe heart, liver, lung, kidney diseases and other serious system diseases; 2. With metal implants such as cardiac pacemakers, coronary stents and aneurysm clips, or with ferromagnetic materials such as cochlear implants; 3. Severe aphasia, agnosia, apraxia and deafness; 4. Patients with serious eye diseases and skin diseases.

Design outcomes

Primary

MeasureTime frame
Difference in PSQI scale scores before and after treatment;

Secondary

MeasureTime frame
Wearable devices monitor sleep data;Melatonin and reactive oxygen species levels in the blood;Excitatory and inhibitory neurotransmitters;

Countries

China

Contacts

Public ContactYueqing Hu

Beijing Geriatric Hospital

hyqing1987@163.com+86 136 8304 6909

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026